New Delhi: GlaxoSmithKline Pharmaceuticals Ltd on Wednesday announced recall of ranitidine hydrochloride tablets produced in India using API sourced from Saraca Laboratories Ltd following detection of genotoxic nitrosamine NDMA by authorities. The company has also decided to suspend release, distribution and supply of all dose forms of ranitidine hydrochloride products to all markets, including India, as a precautionary action pending the outcome of ongoing tests and investigations, GlaxoSmithKline Pharmaceuticals said in a regulatory. GSK Pharma said it has been contacted by regulatory authorities regarding detection of genotoxic nitrosamine NDMA in ranitidine products.